Genomic medicine and risk prediction across the disease spectrum

Abstract

Genomic medicine is based on the knowledge that virtually every medical condition, disease susceptibility or response to treatment is caused, regulated or influenced by genes. Genetic testing may therefore add value across the disease spectrum, ranging from single-gene disorders with a Mendelian inheritance pattern to complex multi-factorial diseases. The critical factors for genomic risk prediction are to determine: (1) where the genomic footprint of a particular susceptibility or dysfunction resides within this continuum, and (2) to what extent the genetic determinants are modified by environmental exposures. Regarding the small subset of highly penetrant monogenic disorders, a positive family history and early disease onset are mostly sufficient to determine the appropriateness of genetic testing in the index case and to inform pre-symptomatic diagnosis in at-risk family members. In more prevalent polygenic non-communicable diseases (NCDs), the use of appropriate eligibility criteria is required to ensure a balance between benefit and risk. An additional screening step may therefore be necessary to identify individuals most likely to benefit from genetic testing. This need provided the stimulus for the development of a pathology-supported genetic testing (PSGT) service as a new model for the translational implementation of genomic medicine in clinical practice. PSGT is linked to the establishment of a research database proven to be an invaluable resource for the validation of novel and previously described gene-disease associations replicated in the South African population for a broad range of NCDs associated with increased cardio-metabolic risk. The clinical importance of inquiry concerning family history in determining eligibility for personalized genotyping was supported beyond its current limited role in diagnosing or screening for monogenic subtypes of NCDs. With the recent introduction of advanced microarray-based breast cancer subtyping, genetic testing has extended beyond the genome of the host to also include tumor gene expression profiling for chemotherapy selection. The decreasing cost of next generation sequencing over recent years, together with improvement of both laboratory and computational protocols, enables the mapping of rare genetic disorders and discovery of shared genetic risk factors as novel therapeutic targets across diagnostic boundaries. This article reviews the challenges, successes, increasing inter-disciplinary integration and evolving strategies for extending PSGT towards exome and whole genome sequencing (WGS) within a dynamic framework. Specific points of overlap are highlighted between the application of PSGT and exome or WGS, as the next logical step in genetically uncharacterized patients for whom a particular disease pattern and/or therapeutic failure are not adequately accounted for during the PSGT pre-screen. Discrepancies between different next generation sequencing platforms and low concordance among variant-calling pipelines caution against offering exome or WGS as a ...

Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries

“…Towards this goal, a pathology-supported genetic testing approach could prove useful in developing standardized pre-screen diagnostic algorithms to select non-responders to standard therapies and genetically uncharacterized NAFLD patients set to derive additional benefit from extended whole genome or exome sequencing [191,192] . Next-generation sequencing could be used to validate common susceptibility variants implicated in the etiopathogenesis of NAFLD, thereby supporting the development and validation of a genomics-based screening panel to provide greater insight into the value of personalized medicine applications [193,194] .…”

Genetics in the 21st Century: Implications for patients, consumers and citizens

“…Each of these genes will have different links to cancer, thus increasing the complexity of the results that emerge. In addition to using genomic technology to understand the genetic basis of an existing condition such as breast cancer, it can also be used to uncover a new diagnosis for a previously undescribed rare condition 6 . Again, here the key change is the volume of information that will be generated.…”

“…Whilst it is unrealistic to suggest that all 20,000 genes will be analysed and reported as a whole 7 , the resource is at least available to be interrogated as and when required. Genomic medicine is now available across whole healthcare systems, it has been truly ‘mainstreamed’ 6, 8 . Thus, patients have more exposure than ever before to the volume and complexity of genetic information.…”

Development to Enable Precision Medicine in Africa

“…Since genomic medicine assumes disease susceptibility, severity or response to treatment is associated with genetic variation, gene expression or epigenetics, genetic testing is essential for multiple diseases, including single gene disorders with a Mendelian inheritance pattern as well as complex multifactorial diseases [15]. Scientists should partner with pharmaceutical companies for translational medicine and need to solicit commitment from their governments to establish facilities for enabling translational research and routine genetic testing and interpretation.…”